

DAFTAR PUSTAKA

- Abba, M., Patil, N., & Allgayer, H., 2014. MicroRNAs in the Regulation of MMPs and Metastasis. *Cancers*, 6(2), 625–45.
- Ali, AY., Farrand, L., Kim, JY., Byun, S., Suh, JY., Lee, HJ., Tsangi, BK. 2012. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. *Ann. N.Y. Acad. Sci.*, 1271, Pages : 58–67
- Aziz, FM. 2009. Gynecological Cancer in Indonesia. *J Gynecol Oncol*, 20(1):pp.8-10
- Baranwal, S., & Alahari, S. K., 2010. miRNA control of tumor cell invasion and metastasis. *Int J Cancer* 126(6): 1283–1290.
- Brabletz T .2012.To differentiate or not—routes towards metastasis. *Nature Reviews Cancer* 12: 425–436.
- Berek, JS; Fu, YS; Hacker, NF. 2002. *Ovarian Cancer in Novak's Gynecology 13th Edition*. Williams & Wilkins, Pennsylvania : pp.1245-1320.
- Blondal, T., Jensby Nielsen, S., Baker, A., Andreasen, D., Mouritzen, P., Wrang Teilum, M., & Dahlsveen, IK., 2013, Assessing sample and miRNA profile quality in serum and plasma or other biofluids. *Methods*, 59(1), S1–6
- Bouyssou, JMC., Manier, S., Huynh, D., Issa, S., Roccaro, AM., & Ghobrial, IM., 2014. Regulation of microRNAs in cancer metastasis. *Biochim Biophys Acta*, 1845(2), 255–65.
- Britton, C., Winter, A. D., Gillan, V., & Devaney, E., 2014, MicroRNAs of Parasitic Helminths – Identification, Characterization and Potential as Drug Targets. *Int J Parasitol Drugs Drug Resist*, 4(2), 85–94.
- Buys, SS., Partridge, E., Black, A., *et al.*, 2011. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. *J Am Med Assoc*, 22 : pp.2295– 2302.
- Calin, G. a, & Croce, C. M., 2006. MicroRNA signatures in human cancers. *Nature Rev Cancer* 6(11): 857–66.
- Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, et al. (2010). Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non–small cell lung cancer. *Int J Cancer* 8: 1207– 1216.

- Chandi, C. Mandal, A. Nag, S. Kumar. 2015. A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential. *16(12)*: 1381 – 1403.
- Chen, B., Li, H., Zeng, X., Yang, P., Liu, X., Zhao, X., & Liang, S., 2012, Roles of microRNA on cancer cell metabolism. *J Transl Med*, 10, 228.
- Chen, H.-C., Chen, G.-H., Chen, Y.-H., Liao, W.-L., Liu, C.-Y., Chang, K.-P., *et al.*, 2009. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. *Br J Cancer*, 100(6): 1002–11.
- Chen, Xi., Zhang, Junfeng, Zen, Ke., Zhang, Chen-Yu, 2008, 2011. MicroRNAs as Blood-based Biomarkers of Cancer. Dalam Cho, C. S. William (Eds). *MicroRNAs in Cancer Translational Research*. Springer : Pp.499-532
- Chen, Y., Lan, Q., Zheng, T., Zhao, N., Holford, T. R., Lerro, C., *et al.*, 2013. Polymorphisms in JAK/STAT Signaling Pathway Genes and Risk of Non-Hodgkin Lymphoma. *Leuk Res*37(9): 1120–1124.
- Chinen, T., Komai, K., Muto, G., Morita, R., Inoue, N., Yoshida, H., *et al.*, 2011. Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. *Nat Commun*, 2(2): 190.
- Cullen, B. R., 2013. MicroRNAs as Mediators of Viral Immune Evasion Bryan. *Nat Immunol.*, 14(3): 205–210.
- De Martel C., Ferlay J., Franceschi S., 2012. Global Burden of Cancer Attributable to Infections in 2008: A Review and Synthetic Analysis. *Lancet Oncol*, 13 :607-615.
- Gao, Y.C. and Wu J. 2015. MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. *Tumour biology : International Society for Oncodevelopmental Biology and Medicine*. 36:4843–4850.
- Garzon, R., Marcucci, G., Croce, CM. 2010. Targeting microRNAs in cancer : rationale, strategies and challenges. *Nat Rev Drug Discov*, 9(10) : pp.775-789
- George, G.P. dan Mittal, R.D. 2010. microRNAs : Potential Biomarker in Cancer. *Indian J Clin Biochem*, (1) : pp. 4-14

- Goda G Muralidhar dan Maria V Barbolina. 2015. The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. *Int. J. Mol. Sci.* 16 : pp.16833-16847
- Hammell, M., Long, D., Zhang, L., Lee, A., Carmack, S., Han, M., *et.al.* 2008. mirWIP: microRNA Target Prediction Based on miRNP Enriched Transcripts. *Nat Methods*, 5(9) : pp.813–819
- Harrison, D.A., 2012. The Jak/STAT pathway. *Cold Spring Harb Perspect Biol*, 4(3): 2012–2015.
- Huang, Y., Yang, Y. B., Zhang, X. H., Yu, X. L., Wang, Z. B., *et al.*, 2013. MicroRNA-21 gene and cancer. *Med Oncol* 30(376).
- IAIRC, 2014, *World Cancer Report 2014*.
- Iorio, M. V, & Croce, C. M., 2012. MicroRNA dysregulation in cancer : diagnostics , monitoring and therapeutics . A comprehensive review. *EMBO Mol Med*, 143–159.
- Jaime Prat. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: a bridged republication. 2015. *Gynecol Oncol*, 26 (2) : pp.87-89
- Jelovac, D; Armstrong, DK. 2011. Recent Progress in the Diagnosis and treatment of Ovarian Cancer. *Ca Cancer J Clin*, 61 : pp.183–203
- Kaku, Tsunehisa; Ogawa, Shinji; Kawano, Yfoshiaki; Ohishi, Yoshihiro; Kobayashi, Hiroaki; Hirakawa, Toshio; Nakano, Hitoo 2003. Histological classification of ovarian cancer. *Med Electron Microsc*, 36 : pp.9–17
- Kosaka, N., Iguchi, H., & Ochiya, T., 2010. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. *Cancer Sci*, 101(10): 2087–92.
- Krol, J., Loedige, I., & Filipowicz, W., 2010. The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet*, 11(9): 597–610.
- Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y, Baba H. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. *Annals of surgical oncology*. 2012; 19.3:S656–664.
- Lee, A. W. M., Au, J. S. K., Teo, P. M. L., Leung, T. W., Chua, D. T. T., Sze, W. M., *et al.*, 2004, Staging of Nasopharyngeal Carcinoma: Suggestions for

Improving the Current UICC / AJCC Staging System, *Clin Oncol (R Coll Radiol)* 1, 269–276.

Lee, Y. S., & Dutta, A., 2010. MicroRNAs in cancer. *Annu Rev Pathol* (4): 199–227.

Leitner, A., 2009, *MicroRNA Target Prediction : Institute of Genomic and Bioinformatics*. Graz University of Technology (Unpublished).

Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., & Vasconcelos, M. H., 2011. MicroRNA regulation of core apoptosis pathways in cancer. *Eur J Cancer*,47(2): 163–74.

Lin, Z., & Flemington, E. K., 2011. miRNAs in the pathogenesis of oncogenic human viruses Zhen. *Cancer Lett*,305(2): 186–199.

Liu, Michelle X; Chan, David W; Ngan, Hextan YS. 2012. Mechanisms of Chemoresistance in Human Ovarian Cancer at a Glance. *Gynecol Obstet*, 2 : 3

Liu, L., Li, W., Wei, X., Cui, Q., Lou, W., Wang, G., *et al.*, 2013. Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma. *Gene Ther*,20(1): 84–92.

Liu L, Qiu M, Tan G, Liang Z, Qin Y, Chen L, Chen H, Liu J. 2014.miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. *Journal of translational medicine*. 12:305.

Livak, KJ., Schmittgen, TD. 2001. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta Cq}$ Method. *METHODS*, 25 : pp. 402–408

Lodes, MJ; Caraballo, M; Suciū, D; Munro, S; Kumar, A; Anderson, B. 2009. Detection of cancer with serum miRNAs on an oligonucleotide microarray. *PLoS ONE*, 4 : pp.6229

Lu, J., Xu, X., Liu, X., Peng, Y., Zhang, B., Wang, L., *et al.*, 2014. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. *Br J Cancer*110(2): 392–8.

Mao, F., Leung, WY., Xin, X. 2007. Characterization of EvaGreen and the implication of its physicochemical properties for qPCR applications. *BMC Biotechnology*, 7 : 76

- Menor, M., Ching, T., Zhu, X., Garmire, D., Garmire, LX. 2014. mirMark: a site-level and UTR-level classifier for miRNA target prediction. *Genome Biology*, 15 : pp.500
- Nakada, C. Matsuura, K. Tsukamoto, Y. Tanigawa, M. Yoshimoto, T. Narimatsu, T. Nguyen, *et al.* 2008. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. *The Journal of pathology*. 216:418–427.
- Ng Ek., Chong W. W., Jin H. 2009. Differential Expression of microRNAs in Plasma of Patients with Colorectal Cancer: a Potential marker for Colorectal Screening. *Gut*, 58:1375-81.
- Nicolleta Colombo. 2014. Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. *European Journal of Cancer Supplements*. 12(2) : pp.7–12
- Noonan, E. J., Place, R. F., Li, L. C., 2008, 2011. MicroRNAs in Predicting Radiotherapy and Chemotherapy Response. Dalam Cho, C. S. William (Eds). *MicroRNAs in Cancer Translational Research*. Springer : Pp.415-448.
- Pacurari M, Addison JB, Bondalapati N, Wan Y-W, Luo D. (2013). The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. *International journal of oncology* 43: 548–560.
- Pedro M Costa dan Maria C Pedroso de Lima. 2013. MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. *Pharmaceuticals*, 6(10) : 1195–1220
- Pi-Lin, S; Yen-Hou, C; Kuan-Chong, C; Chi-Mu, C. 2014. Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review. *Gynecologic Oncology*, 133 : 147–154
- Pritchard, CC., Cheng, HH., Tewari, M. 2012. microRNA profiling : approaches and considerations. *Nat Rev*. 13 : 358-69
- Rosen, DG; Yang, GL; Guangzhi; Mercado-Uribe, I; Chang, B; Xoai, XZ; *et.al.* 2010. Ovarian cancer: pathology, biology, and disease models. *Front Biosci*, 14 : 2089-2102
- Ruly Widagdo. 2009. *Angka Harapan Hidup Penderita Kanker Ovarium di Rumah Sakit Sardjito*. Tesis Fakultas Kedokteran Universitas Gadjah Mada

- Rusnita, T; Prijono, I. Ekspresi P53, Bcl-2 dan Nm23-H1 pada Karsinoma Ovarium Tipe Serosum dan Musinosum serta Hubungannya dengan Stadium dan Derajat Histologi. *Majalah Patologi*; 23(2) : 13-19
- Sasi, W., Sharma, A. K., & Mokbel, K., 2014. The role of suppressors of cytokine signalling in human neoplasms. *Mol Biol Int*.
- Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K., 2014. Clinical relevance of circulating cell-free microRNAs in cancer. *Nat Rev Clin Oncol*, 11(3):145-56.
- Song, C. Liu, L.Z. Pei, X.Q. Liu, X. Yang, L. Ye, F. Xie, X. Chen, J. Tang, H. Xie, X. 2015. miR-200c inhibits breast cancer proliferation by targeting KRAS. *Oncotarget*. 6(33):34968-78.
- Soslow, A Robert. 2008. Histologic Subtypes of Ovarian Carcinoma: An Overview. *International Journal of Gynecological Pathology*, 27 : 161–174
- Tang, H., Deng, M. Tang, Y. Xie, X. Guo, J. Kong, Y. Ye, F. Su, Q. Xie, X. 2013. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. *Clinical cancer research. American Association for Cancer Research*. 19:5602–5612.
- Tejero, R., Navarro, A., Campayo, M., Vinolas, N., Marrades, RM., Cordeiro. A., *et.al*. 2014. miR-141 and miR-200c as Markers of Overall Survival in Early Stage Non-Small Cell Lung Cancer Adenocarcinoma. *PLoS ONE* 9(7): e101899.
- Teng, Y. X. Su, X. Zhang, Y. Zhang, C. Li, W. Niu, C. Liu, K. Qu. 2016. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations. *Oncotarget*.
- Vester, B dan Wengel, J. 2004. LNA (Locked Nucleic Acid) : High Affinity Targeting of Complementary RNA and DNA. *Biochemistry*, 23(42) : 13233-40
- Wang, L., Wang, C., Jin, S., Donghui, Q., Huanchun, Y. 2015. Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance. *Int J Clin Exp Pathol*, 8(9) : 10953-10963
- Wang, WT; Zhao, YN; Yan, JX; Weng, MY; Wang, Y; Chen, YQ; *et.al*. 2014. Differentially expressed microRNAs in the serum of cervical squamous cell

carcinoma patients before and after surgery. *Journal of Hematology and Oncology*, 7 : 6

Wang, J; Zhang, KY; Liu, SM; Sen, S. 2014. Tumor-Associated Circulating MicroRNAs as Biomarkers of Cancer. *Molecules*, 19 : 1912-1938

Wen-Tao, W. dan Chen, Y-Q., 2014, Circulating miRNAs in Cancer : from Detection to Therapy. *Journal of Hematology and Oncology*, 7 : 86

William, C.S, Cho. 2011. MicroRNAs in Cancer Translational Research. New York : Springer.

Yu DS, Lv G, Mei XF, Cao Y, Wang YF, Wang YS, Bi YL. 2014. MiR-200c regulates ROS-induced apoptosis in murine BV-2 cells by targeting FAP-1. *Spinal cord*. 2014.185.

Zeng, X., Xiang, J., Wu, M., Xiong, W., Tang, H., Deng, M., *et al.*, 2012. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. *PloS One*,7(10).

Zhang, Y., Liu, D., Chen, X., Li, J., Li, L., Bian, Z., *et al.*, 2010. Article Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell Migration. *Mol Cell*,39: 133–144.

Zubakov, D.,Boersma, A.W.M., Choi,Y., van Kuijk, P.F., Wiemer, E.A.C., Kayser, M. 2010. MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation. *Int J Legal Med*,(124):217-226.